Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain

Abstract

Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO) have been demonstrated in randomized clinical trials (RCTs). However, data regarding its efficacy and safety in real-life settings are scarce.

Objectives: To evaluate the efficacy and safety of secukinumab in clinical practice in patients with PsO attending 10 dermatology centers in Spain.

Methods: Data from 136 patients consecutively treated with secukinumab for at least 52 weeks were collected in a retrospective observational study.

Results: After 52 weeks of treatment, 69% and 46% of patients achieved a PASI-75, PASI-90, respectively. PASI-score ≤5 was achieved in 83% of patients, PASI-score ≤3 in 73% and PASI-score ≤1 in 47%. Response rates were found significantly lower in patients with obesity and non-naïve to biologics (p < .05). The most common adverse event (AE) was candidiasis (5/136). Thirty-six patients (26.5%) discontinued treatment by week 52 due to lack or loss of response (n = 29), AEs (n = 2) or other causes (n = 5).

Conclusion: These findings complement the efficacy and safety profiles of secukinumab in PsO outlined in RCTs. The effectiveness in clinical practice may be lower in patients with a BMI ≥30 and those previously treated with other biologic agents.

Keywords:

• Psoriasis
• biologics
• secukinumab
• safety
• effectiveness
• daily clinical practice

Disclosure statement

J. Notario has perceived consultancy/speakers honoraria and/or participated in clinical trials sponsored by AbbVie, Almirall, Celgene, Gebro, Janssen, Leo Pharma, Lilly, MSD, Novartis and Pfizer. G. Deza, F. Valentí, M. Alsina and J. Riera have no conflicts of interest to declare. E. Vilarrasa has received consultancy/speakers’ honoraria and participated in clinical trials sponsored by Abbvie, Janssen, MSD, Novartis, and Pfizer. C. Muñoz has received research grants and/or fees for scientific advice or talks from Pfizer, Abbvie, Janssen, Bial, Almirall, Novartis, and Celgene. J. Mollet has received honoraria as a speaker from Novartis and Janssen. V. Rocamora has received honoraria as a speaker from Novartis and Janssen. J. M. Carrascosa has received institutional grants/research support from AbbVie, Novartis, honoraria or consultation fees from Abbvie, Almirall, Amgen, Biogen, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer and has served as a speaker for Celgene, Lilly, Janssen, Novartis, Abbvie, Gebro, Biogen, and Pfizer. E. Alcazar has perceived speakers honoraria from Abbvie, Janssen, Novartis and Leo Pharma and participated in clinical trials sponsored by Novartis. D. Vidal has participated in clinical trials and received honoraria as a speaker from Novartis. L. Puig has participated in clinical trials and/or received honoraria as a consultant, investigator, speaker or advisory board member from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Janssen, Eli Lilly and Company, Leo Pharma, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and Sanofi. A. López-Ferrer has received consultancy/speakers’ honoraria and participated in clinical trials sponsored by Abbvie, Janssen, MSD, Novartis, and Pfizer. F. Gallardo and M. Ferran have participated in clinical trials and/or received honoraria as a consultant, investigator, speaker from AbbVie, Celgene, Janssen, Lilly, Leo Pharma, MSD, Novartis, Pfizer. None of the aforementioned has relation to the present work.